Expert consensus on brachytherapy for recurrent cervical cancer
Jiang Ping1, Zhang Fuquan2, Cheng Guanghui3, Wang Ruoyu4, Sun Baosheng5, Wang Tiejun6, Zhang Yunyan7, Qu Ang1, Wang Junjie1
1Department of Radiation Oncology, Peking University Third Hospital, Beijing 100191, China; 2Department of Radiation Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China; 3Department of Radiation Oncology, China-Japan Union Hospital of Jilin University, Changchun 130033, China; 4Department of Radiation Oncology, Affiliated Zhongshan Hospital of Dalian University, Dalian 116001, China; 5Department of Radiation Oncology, Jilin Cancer Hospital, Changchun 130012, China; 6Department of Radiation Oncology, The Second Hospital of Jilin University, Changchun 130041, China; 7Department of Radiation Oncology, Affiliated Cancer Hospital of Harbin Medical University, Harbin 150081, China
Abstract：The main treatment options for cervical cancer include surgery and/or radiotherapy combined with chemotherapy. Radiotherapy consists of external beam radiotherapy and brachytherapy (BT). BT contains high-dose-rate (HDR-BT) and low-dose-rate brachytherapy (LDR-BT). The prognosis of cervical cancer is relatively good. However, some patients experience substantial treatment failures, such as intra-pelvic and/or extra-pelvic recurrences. Recurrent cervical cancer (RCC) has poor prognosis due to lack of effective and safe approach. In 2002, Professor Wang Junjie introduced CT-guidance into the field of LDR-BT, and fully applied 3D printing technology in BT in 2015, which met the requirement of preoperative LDR-BT planning, and significantly improving the precision, quality and efficiency of BT. In 2018, Professor Wang Junjie proposed the concept of stereotactic ablation brachytherapy (SABT). Chinese experts have attempted to treat RCC with BT for nearly two decades and accumulated certain clinical experience. Based on the 3D-printing template (3D-PT) assisted CT-guidance, the standard and consensus of BT for RCC were established, including the indications, dosimetric requirements, technological procedures and radiation protection, etc. At present, there is still a lack of phage Ⅲ clinical and evidence-based medicine for the treatment of RCC with 3D-PT guidance, which requires prospective multi-center, randomized studies to improve the evidence-based level of BT.
Jiang Ping,Zhang Fuquan,Cheng Guanghui et al. Expert consensus on brachytherapy for recurrent cervical cancer[J]. Chinese Journal of Radiation Oncology, 2020, 29(9): 721-729.
[1] Friedlander M, Grogan M. Guidelines for the treatment of recurrent and metastatic cervical cancer[J]. Oncologist, 2002,7(4):342-347. [2] Perez CA, Grigsby PW, Camel HM, et al. Irradiation alone or combined with surgery in stage Ⅰ b, ⅡA, and ⅡB carcinoma of uterine cervix:update of a nonrandomized comparison[J]. Int J Radiat Oncol Biol Phys, 1995, 31(4):703-716. DOI:10.1016/0360-3016(94)00523-0. [3] Marchiolé P, Buénerd A, Benchaib M, et al. Clinical significance of lymphovascular space involvement and lymph node micrometastases in early-stage cervical cancer:a retrospective case-control surgicopathological study[J]. Gynecol Oncol, 2005, 97(3):727-732. DOI:10.1016/j.ygyno.2005.01.004. [4] Fagundes H, Perez CA, Grigsby PW, et al. Distant metastases after irradiation alone in carcinoma of the uterine cervix[J]. Int J Radiat Oncol Biol Phys, 1992, 24(2):197-204. DOI:10.1016/0360-3016(92)90671-4. [5] Peiretti M, Zapardiel I, Zanagnolo V, et al. Management of recurrent cervical cancer:a review of the literature[J]. Surg Oncol, 2012, 21(2):e59-e66. DOI:10.1016/j.suronc.2011.12.008. [6] van Nagell JJ, Rayburn W, Donaldson ES, et al. Therapeutic implications of patterns of recurrence in cancer of the uterine cervix[J]. Cancer, 1979, 44(6):2354-2361. DOI:10.1002/1097-0142(197912)44:6<2354::aid-cncr2820440653>3.0.co;2-j. [7] Webb MJ, Symmonds RE. Site of recurrence of cervical cancer after radical hysterectomy[J]. Am J Obstet Gynecol, 1980, 138(7 Pt 1):813-817. DOI:10.1016/s0002-9378(16)32742-9. [8] Jurado M, Alcazar JL, Martinez-Monge R. Resectability rates of previously irradiated recurrent cervical cancer (PIRCC) treated with pelvic exenteration:is still the clinical involvement of the pelvis wall a real contraindication a twenty-year experience[J]. Gynecol Oncol, 2010,116(1):38-43. DOI:10.1016/j.ygyno.2009.09.035. [9] Quinn MA, Benedet JL, Odicino F, et al. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer[J]. Int J Gynaecol Obstet, 2006,95(Suppl 1):S43-S103. DOI:10.1016/S0020-7292(06)60030-1. [10] Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer[J]. N Engl J Med, 1999, 340(15):1144-1153. DOI:10.1056/NEJM199904153401502. [11] Perez CA, Camel HM, Kao MS, et al. Randomized study of preoperative radiation and surgery or irradiation alone in the treatment of stage Ⅰ b and ⅡA carcinoma of the uterine cervix:final report[J]. Gynecol Oncol, 1987, 27(2):129-140. DOI:10.1016/0090-8258(87)90285-x. [12] Wang CJ, Lai CH, Huang HJ, et al. Recurrent cervical carcinoma after primary radical surgery[J]. Am J Obstet Gynecol, 1999, 181(3):518-524. DOI:10.1016/s0002-9378(99)70486-2. [13] Hong JH, Tsai CS, Lai CH, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy[J]. Int J Radiat Oncol Biol Phys, 2004, 60(1):249-257. DOI:10.1016/j.ijrobp.2004.02.044. [14] Dornhofer N, Hockel M. New developments in the surgical therapy of cervical carcinoma[J]. Ann N Y Acad Sci, 2008, 1138:233-252. DOI:10.1196/annals.1414.029. [15] Hockel M, Sclenger K, Hamm H, et al. Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall[J]. Cancer, 1996, 77(9):1918-1933. DOI:10.1002/(SICI)1097-0142(19960501)77:9<1918::AID-CNCR24>3.0. CO;2-1. [16] Barber HR. Relative prognostic significance of preoperative and operative findings in pelvic exenteration[J]. Surg Clin North Am, 1969, 49(2):431-447. DOI:10.1016/s0039-6109(16)38800-4. [17] Berek JS, Howe C, Lagasse LD, et al. Pelvic exenteration for recurrent gynecologic malignancy:survival and morbidity analysis of the 45-year experience at UCLA[J]. Gynecol Oncol, 2005,99(1):153-159. DOI:10.1016/j.ygyno.2005.05.034. [18] Qu A, Jiang P, Sun H, et al. Efficacy and dosimetry analysis of image-guided radioactive 125I seed implantation as salvage treatment for pelvic recurrent cervical cancer after external beam radiotherapy[J]. J Gynecol Oncol, 2019,30(1):e9. DOI:10.3802/jgo.2019.30.e9. [19] 曲昂, 王俊杰, 姜伟娟, 等. 125I粒子植入挽救性治疗放疗后盆腔复发宫颈癌的疗效分析[J]. 中华核医学与分子影像杂志, 2018,38(1):17-21. DOI:10.3760/cma.j.issn.2095-2848.2018.01.005. Qu A, Wang JJ, Jiang WJ, et al. Efficacy of 125I seeds implantation for pelvic recurrence of cervical cancer after radiotherapy[J]. Chin J Nucl Med Mol Imag, 2018, 38(1):17-21. DOI:10.3760/cma.j.issn.2095-2848.2018.01.005. [20] 姜玉良, 王皓, 吉喆, 等. CT引导辅助3D打印个体化非共面模板指导125I粒子治疗盆腔复发肿瘤剂量学研究[J]. 中华放射肿瘤学杂志, 2016,25(9):959-964. DOI:10.3760/cma.j.issn.1004-4221.2016.09.012. Jiang YL, Wang H, Ji Z, et al.CT image-guided and personalized 3D printed template-assisted 125I seed implantation for recurrent pelvic tumor:a dosimetric study[J].Chin J Radiat Oncol,2016,25(9):959-964. DOI:10.3760/cma.j.issn.1004-4221.2016.09.012. [21] 孙海涛, 姚丽红, 王俊杰, 等. 3D打印非共面模板引导125I粒子组织间近距离治疗盆腔肿瘤个体化设计[J]. 中华放射医学与防护杂志, 2017,37(7):485-489. DOI:10.3760/cma.j.issn.0254-5098.2017.07.002. Sun HT, Yao LH, Wang JJ, et al. 3D-printing non-coplanar template assisted 125I seed implantation for pelvic tumor:individual template design method[J]. Chin J Radiol Med Prot, 2017,37(7):485-489. DOI:10.3760/cma.j.issn.0254-5098.2017.07.002. [22] 江萍, 郭福新, 姜玉良, 等. 3D打印非共面模板辅助CT引导125I粒子植入治疗盆腔复发宫颈癌的剂量学研究[J]. 中华放射医学与防护杂志, 2017,37(7):490-494. DOI:10.3760/cma.j.issn.0254-5098.2017.07.003. Jiang P, Guo FX, Jiang YL, et al. 3D-printing non-coplanar template assisted CT-guided 125I seed implantation on pelvic recurrent cervical cancer[J]. Chin J Radiol Med Prot, 2016, 36(9):662-666. DOI:10.3760/cma.j.issn.0254-5098.2017.07.003. [23] 曲昂, 彭冉, 姜玉良, 等. 3D打印共面坐标模板辅助125I放射性粒子植入治疗盆壁复发宫颈癌的剂量学研究[J]. 中华放射医学与防护杂志, 2018, 38(10):756-760. DOI:10.3760/cma.j.issn.0254-5098.2018.10.007. Qu A, Peng R, Jiang YL, et al. Dosimetric study of 125I seed implantation by 3D-printing coplanar template for pelvic wall recurrent cervical cancer after radiotherapy[J]. Chin J Radiol Med Prot, 2018, 38(10):756-760. DOI:10.3760/cma.j.issn.0254-5098.2018.10.007. [24] 曲昂, 王俊杰, 姜玉良, 等. 3D打印非共面模板与共面坐标模板辅助放射性粒子植入治疗盆壁复发妇科肿瘤的术前计划对比[J]. 中华医学杂志, 2019,99(11):841-843. DOI:10.3760/cma.j.issn.0376-2491.2019.11.009. Qu A, Wang JJ, Jiang YL, et al. Comparison of preoperative planning of radioactive seed implantation for pelvic wall recurrent gynecological malignant tumors between 3D-printing non-coplanar template and 3D-printing coplanar template[J]. Natl Med J China, 2019, 99(11):841-843. DOI:10.3760/cma.j.issn.0376-2491.2019.11.009. [25] Ji Z, Jiang YL, Guo FX, et al. Dosimetry verification of radioactive seed implantation with 3D printing template and CT guidance for paravertebral/retroperitoneal malignant tumor[J]. Chin J Med, 2017, 97(13):996-1000. DOI:10.3760/cma.j.issn.0376-2491.2017.13.007. [26] Wang J, Chai S, Zheng G, et al. Expert consensus statement on computed tomography-guided 125I radioactive seeds permanent interstitial brachytherapy[J]. J Cancer Res Ther, 2018, 14(1):12-17. DOI:10.4103/jcrt. JCRT_888_17. [27] 王俊杰. 3D打印技术在精准粒子植入治疗中的应用[J]. 中华放射医学与防护杂志, 2017,37(7):481-484. DOI:10.3760/cma.j.issn.0254-5098.2017.07.001. Wang JJ. Application of 3D-printing in accurate seed implantation therapy[J]. Chin J Radiol Med Prot, 2017, 37(7):481-484. DOI:10.3760/cma.j.issn.0254-5098.2017.07.001. [28] Viswanathan AN, Erickson BA. Three-dimensional imaging in gynecologic brachytherapy:a survey of the American Brachytherapy Society[J]. Int J Radiat Oncol Biol Phys, 2010, 76(1):104-109. DOI:10.1016/j.ijrobp.2009.01.043. [29] Hareyama M, Sakata K, Oouchi A, et al. High-dose-rate versus low-dose-rate intracavitary therapy for carcinoma of the uterine cervix:a randomized trial[J]. Cancer, 2002, 94(1):117-124. DOI:10.1002/cncr.10207. [30] Nag S, Erickson B, Thomadsen B, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix[J]. Int J Radiat Oncol Biol Phys, 2000, 48(1):201-211. DOI:10.1016/s0360-3016(00)00497-1. [31] Quero L, Guillerm S, Taright N, et al. 10-Year follow-up of 621 patients treated using high-dose rate brachytherapy as ambulatory boost technique in conservative breast cancer treatment[J]. Radiother Oncol, 2017, 122(1):11-16. DOI:10.1016/j.radonc.2016.06.014. [32] Holm HH, Juul N, Pedersen JF, et al. Transperineal 125Iodine seed implantation in prostatic cancer guided by transrectal ultrasonography[J]. J Urol, 1983, 130(2):283-286. DOI:10.1016/s0022-5347(17)51108-8. [33] 姜玉良, 马月, 王俊杰, 等. 125I粒子治疗头颈部肿瘤颈淋巴结放疗后复发的结果分析[J]. 中华放射肿瘤学杂志, 2011,20(2):91-94. DOI:10.3760/cma.j.issn.1004-4221.2011.02.002. Jiang YL, Ma Y, Wang JJ, et al. Implantation of 125I seeds for recurrence cervical node of head and neck tumor after external beam radiotherapy[J]. Chin J Radia Oncol, 2011, 20(2):91-94. DOI:10.3760/cma.j.issn.1004-4221.2011.02.002. [34] Jiang YL, Meng N, Wang JJ, et al. CT-guided iodine-125 seed permanent implantation for recurrent head and neck cancers[J]. Radiat Oncol, 2010, 5(1):68. DOI:10.1186/1748-717X-5-68. [35] Ji Z, Jiang Y, Tian S, et al. The effectiveness and prognostic factors of CT-guided radioactive I-125 seed implantation for the treatment of recurrent head and neck cancer after external beam radiation therapy[J]. Int J Radiat Oncol Biol Phys, 2019, 103(3):638-645. DOI:10.1016/j.ijrobp.2018.10.034. [36] Thomas GM, Dembo AJ, Myhr T, et al. Long-term results of concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after surgery[J]. Int J Gynecol Cancer, 1993, 3(4):193-198. DOI:10.1046/j.1525-1438.1993.03040193.x. [37] Maneo A, Landoni F, Cormio G, et al. Concurrent carboplatin/5-fluorouracil and radiotherapy for recurrent cervical carcinoma[J]. Ann Oncol, 1999, 10(7):803-807. DOI:10.1023/a:1008356010556. [38] Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage ⅡB-IVA carcinoma of the cervix with negative para-aortic lymph nodes:a Gynecologic Oncology Group and Southwest Oncology Group study[J]. J Clin Oncol, 1999, 17(5):1339-1348. DOI:10.1200/JCO.1999.17.5.1339. [39] Morris M, Eifel J, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer[J]. N Engl J Med, 1999, 340(15):1137-1143. DOI:10.1056/NEJM199904153401501. [40] Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ⅰ b cervical carcinoma[J]. N Engl J Med, 1999, 340(15):1154-1161. DOI:10.1056/NEJM199904153401503. [41] Small WJ, Beriwal S, Demanes DJ, et al. American Brachytherapy Society consensus guidelines for adjuvant vaginal cuff brachytherapy after hysterectomy[J]. Brachytherapy, 2012, 11(1):58-67. DOI:10.1016/j.brachy.2011.08.005. [42] Boussios S, Seraj E, Zarkavelis G, et al. Management of patients with recurrent/advanced cervical cancer beyond first line platinum regimens:Where do we stand? A literature review[J]. Crit Rev Oncol Hematol, 2016, 108(2):164-174. DOI:10.1016/j.critrevonc.2016.11.006. [43] Windschall A, Ott OJ, Sauer R, et al. Radiation therapy and simultaneous chemotherapy for recurrent cervical carcinoma[J]. Strahlenther Onkol, 2005, 181(8):545-550. DOI:10.1007/s00066-005-1340-8. [44] Thigpen T, Shingleton H, Homesley H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix:a phase Ⅱ study of the Gynecologic Oncology Group[J]. Cancer, 1981, 48(4):899-903. DOI:10.1002/1097-0142(19810815)48:<899::aid-cncr2820480406>3.0.co;2-6. [45] Bazhenov AG, Guseinov KD, Khadzhimba AV, et al. Results of treatment for recurrent cancer of the uterine cervix[J]. Vopr Onkol, 2009, 55(3):319-326. [46] Cerrotta A, Gardan G, Cavina R, et al. Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose[J]. Eur J Gynaecol Oncol, 2002, 23(2):115-119. [47] Smaniotto D, D′Agostino G, Luzi S, et al. Concurrent 5-fluorouracil, mitomycin C and radiation with or without brachytherapy in recurrent cervical cancer:a scoring system to predict clinical response and outcome[J]. Tumori, 2005, 91(4):295-301. [48] ICRU. Report 89[J]. J ICRU, 2013, 13(1-2):NP. DOI:10.1093/jicru/ndw042. [49] Fenkell L, Assenholt M, Nielsen SK, et al. Parametrial boost using midline shielding results in an unpredictable dose to tumor and organs at risk in combined external beam radiotherapy and brachytherapy for locally advanced cervical cancer[J]. Int J Radiat Oncol Biol Phys, 2011, 79(5):1572-1579. DOI:10.1016/j.ijrobp.2010.05.031. [50] Huang EY, Lin H, Hsu HC, et al. High external parametrial dose can increase the probability of radiation proctitis in patients with uterine cervix cancer[J]. Gynecol Oncol, 2000, 79(3):406-410. DOI:10.1006/gyno.2000.5997. [51] Akbaba S, Oelmann-Avendano JT, Bostel T, et al. Percutaneous parametrial dose escalation in women with advanced cervical cancer:feasibility and efficacy in relation to long-term quality of life[J]. Radiol Oncol, 2018, 52(3):320-328. DOI:10.2478/raon-2018-0029. [52] Boyle J, Craciunescu O, Steffey B, et al. Methods, safety, and early clinical outcomes of dose escalation using simultaneous integrated and sequential boosts in patients with locally advanced gynecologic malignancies[J]. Gynecol Oncol, 2014, 135(2):239-243. DOI:10.1016/j.ygyno.2014.08.037. [53] Mohamed S, Kallehauge J, Fokdal L, et al. Parametrial boosting in locally advanced cervical cancer:combined intracavitary/interstitial brachytherapy vs. intracavitary brachytherapy plus external beam radiotherapy[J]. Brachytherapy, 2015, 14(1):23-28. DOI:10.1016/j.brachy.2014.09.010. [54] 刘树铭,孙艳,郑磊,等. 外放疗联合碘-125粒子植入治疗头颈癌的临床应用[J]. 北京大学学报(医学版), 2011, 43(1):102-105. DOI:10.3969/j.issn.1671-167X.2011.01.023. Liu SM, Sun Y, Zheng L, et al. Combined external radiotherapy and 125I-particle implantation for treatment of head and neck cancers[J]. J Peking Uni (Heal Sci), 2011, 43(1):102-105. DOI:10.3969/j.issn.1671-167X.2011.01.023. [55] Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2019, 17(5):479-505. DOI:10.6004/jnccn.2019.0023. [56] Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical cancer, version 3.2019, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2019, 17(1):64-84. DOI:10.6004/jnccn.2019.0001. [57] Hockel M, Dornhofer N. Pelvic exenteration for gynaecological tumours:achievements and unanswered questions[J]. Lancet Oncol, 2006, 7(10):837-847. DOI:10.1016/S1470-2045(06)70903-2. [58] Lopez-Graniel C, Dolores R, Cetina L, et al. pre-extenterative chemotherapy, a novel therapeutic approach for patients with persistent or recurrent cervical cancer[J]. BMC Cancer, 2005, 5(1):118. DOI:10.1186/1471-2407-5-118. [59] Chargari C, Mazeron R, Escande A, et al. Image-guided adaptive brachytherapy in cervical cancer:Patterns of relapse by brachytherapy planning parameters[J]. Brachytherapy, 2016, 15(4):456-462. DOI:10.1016/j.brachy.2016.04.006. [60] Viswanathan AN, Cormack R, Rawal B, et al. Increasing brachytherapy dose predicts survival for interstitial and tandem-based radiation for stage ⅢB cervical cancer[J]. Int J Gynecol Cancer, 2009, 19(8):1402-1406. DOI:10.1111/IGC.0b013e3181b62e73. [61] Viswanathan AN, Moughan J, Small WJ, et al. The quality of cervical cancer brachytherapy implantation and the impact on local recurrence and disease-free survival in radiation therapy oncology group prospective trials 0116 and 0128[J]. Int J Gynecol Cancer, 2012, 22(1):123-131. DOI:10.1097/IGC.0b013e31823ae3c9. [62] Mahantshetty U, Kalyani N, Engineer R, et al. Reirradiation using high-dose-rate brachytherapy in recurrent carcinoma of uterine cervix[J]. Brachytherapy, 2014, 13(6):548-553. DOI:10.1016/j.brachy.2014.06.005. [63] Zolciak-Siwinska A, Bijok M, Jonska-Gmyrek J, et al. HDR brachytherapy for the reirradiation of cervical and vaginal cancer:analysis of efficacy and dosage delivered to organs at risk[J]. Gynecol Oncol, 2014, 132(1):93-97. DOI:10.1016/j.ygyno.2013.10.018. [64] Mabuchi S, Takahashi R, Isohashi F, et al. Reirradiation using high-dose-rate interstitial brachytherapy for locally recurrent cervical cancer:a single institutional experience[J]. Int J Gynecol Cancer, 2014, 24(1):141-148. DOI:10.1097/IGC.0000000000000028. [65] Hockel M, Sclenger K, Hamm H, et al. Five-year experience with combined operative and radiotherapeutic treatment of recurrent gynecologic tumors infiltrating the pelvic wall[J]. Cancer, 1996, 77(9):1918-1933. DOI:10.1002/(SICI)1097-0142(19960501)77:9<1918::AID-CNCR24>3.0. CO;2-1. [66] Hockel M. Long-term experience with (laterally) extended endopelvic resection (LEER) in relapsed pelvic malignancies[J]. Curr Oncol Rep, 2015, 17(3):435. DOI:10.1007/s11912-014-0435-8. [67] Hockel M, Horn LC, Einenkel J.(Laterally) extended endopelvic resection:surgical treatment of locally advanced and recurrent cancer of the uterine cervix and vagina based on ontogenetic anatomy[J]. Gynecol Oncol, 2012, 127(2):297-302. DOI:10.1016/j.ygyno.2012.07.120. [68] Singh AK, Grigsby PW, Rader JS, et al. Cervix carcinoma, concurrent chemoradiotherapy, and salvage of isolated paraaortic lymph node recurrence[J]. Int J Radiat Oncol Biol Phys, 2005, 61(2):450-455. DOI:10.1016/j.ijrobp.2004.06.207. [69] Cao Q, Wang H, Meng N, et al. CT-guidance interstitial (125) Iodine seed brachytherapy as a salvage therapy for recurrent spinal primary tumors[J]. Radiat Oncol, 2014,9:301. DOI:10.1186/s13014-014-0301-8. [70] Yao L, Cao Q, Wang J, et al. CT-guided (125) I seed interstitial brachytherapy as a salvage treatment for recurrent spinal metastases after external beam radiotherapy[J]. Biomed Res Int, 2016, 2016:8265907. DOI:10.1155/2016/8265907. [71] 岳瑶, 刘海生, 郭呈祥, 等. 125I粒子治疗前列腺癌医护人员受照剂量分析[J]. 中国现代医学杂志, 2015,25(30):62-64. Yue Y, Liu HS, Guo CX, et al. Evaluation of radiation dose to medical staff during prostate cancer treatment by 125I seeds[J]. Chin J Mod Med, 2015, 25(30):62-64. [72] Cella D, Huang HQ, Monk BJ, et al. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage ⅠVB recurrent or persistent cervical cancer:a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2010, 119(3):531-537. DOI:10.1016/j.ygyno.2010.08.020. [73] Tewari KS, Sill MW, Penson RT, et al. Bevacizumab for advanced cervical cancer:final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)[J]. Lancet, 2017, 390(10103):1654-1663. DOI:10.1016/S0140-6736(17)31607-0.
2020, Vol. 29 
